Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cassava Sciences Inc
(NQ:
SAVA
)
12.35
-6.60 (-34.83%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cassava Sciences Inc
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors
January 24, 2023
Some patients improved while taking the company's twice-daily pill.
Via
Investor's Business Daily
3M, Magna International And Other Big Stocks Moving Lower On Tuesday
January 24, 2023
U.S. stocks traded mostly higher, with the Dow Jones gaining over 50 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Dow Drops 100 Points; Verizon Issues Weak Earnings Forecast
January 24, 2023
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.31% to 33,524.12 while the NASDAQ fell...
Via
Benzinga
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
January 24, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
$100 Invested In Cassava Sciences 5 Years Ago Would Be Worth This Much Today
January 18, 2023
Via
Benzinga
Why Is Cassava Sciences (SAVA) Stock Up 10% Today?
December 07, 2022
Cassava Sciences has completed part of an important Alzheimer’s disease treatment trial. Here's why SAVA stock may rise even more soon.
Via
InvestorPlace
$100 Invested In Cassava Sciences 20 Years Ago Would Be Worth This Much Today
November 16, 2022
Via
Benzinga
Is a Short Squeeze Coming in Cassava Sciences (SAVA) Stock?
January 11, 2023
Today, a rally across most meme stocks has investors looking at Cassava Sciences and SAVA stock due to the short interest in this stock.
Via
InvestorPlace
Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish
January 11, 2023
2023 can be the year of biotechs after two consecutive years of negative or barely positive returns.
Via
Talk Markets
SAVA, LLY, IBB: Why These Alzheimer's Related Stocks Are Volatile On Friday
January 06, 2023
Stocks of companies with Alzheimer's candidates, including Cassava Sciences, Inc. (NASDAQ: SAVA) and Eli Lilly And Company (NYSE: LLY), spiked on Friday after the FDA granted accelerated approval to
Via
Benzinga
Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD
December 20, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Is Anavex Life Sciences a Buy?
December 13, 2022
It still needs to prove that its lead program is as effective as it claims for treating Alzheimer's.
Via
The Motley Fool
Cassava Sciences: Q3 Earnings Insights
November 07, 2022
Cassava Sciences (NASDAQ:SAVA) reported its Q3 earnings results on Monday, November 7, 2022 at 09:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session
December 22, 2022
Gainers Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy.
Via
Benzinga
Tesla, Apple, GameStop, Prometheus Biosciences, Cassava Sciences: Why These 5 Stocks Are Drawing Investors' Attention Today
December 07, 2022
U.S. markets continued their weak trend on Wednesday, with next week’s Federal Open Market Committee meeting beginning to weigh on investors’ minds.
Via
Benzinga
Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease
December 06, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Announces Closing of $50 Million Registered Direct Offering
November 22, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
November 18, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
7 Stocks Rattled by Corporate Scandals and Shenanigans in 2022
November 16, 2022
After getting knocked down by controversy this year, can any of these seven corporate scandal stocks make a recovery?
Via
InvestorPlace
Why Is Cassava Sciences (SAVA) Stock Up Today?
November 14, 2022
Today's big move in Cassava Sciences and SAVA stock has many investors watching this company's trials closer than ever.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
November 14, 2022
Gainers
Via
Benzinga
CASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA
November 11, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Is the Stock Market Open on Election Day 2022?
November 07, 2022
Investors are wondering if the stock market is open on Election Day this year as they seek out extra time to head to the polls!
Via
InvestorPlace
Cassava Sciences Has a Big Warning for SAVA Stock Short Sellers
November 07, 2022
SAVA stock is in the green after reporting earnings. The company also filed a lawsuit against short sellers, alleging misleading statements.
Via
InvestorPlace
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
November 07, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
What the Latest Controversy Really Means for SAVA Stock
November 07, 2022
SAVA stock continues to be dogged by controversy, but the risk/reward proposition for this biotech largely remains the same.
Via
InvestorPlace
Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign
November 03, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Why Is Cassava Sciences (SAVA) Stock Down 10% Today?
November 02, 2022
SAVA stock is in the red after a piece from Probes Reporter accused Cassava of being involved with two undisclosed SEC investigations.
Via
InvestorPlace
A New Study Makes Cassava Sciences Stock an Interesting Buy
October 31, 2022
With the biotech firm moving forward with an open-label study of its Alzheimer's treatment simufilam, SAVA stock is one to watch.
Via
InvestorPlace
Cassava Sciences Announces Expansion of Leadership Team
October 27, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.